PROJECT DETAILS
Therapeutic Area
Oncology
Frameworks
NCCN, ASCO, ICER
Outcome
Category 2A Recommendation
Capabilities
Framework Analysis, Messaging, Payer Strategy
Value Frameworks
Market Access
Oncology
Optimizing Market Positioning Through Value Frameworks
Strategic analysis across NCCN, ASCO, and ICER methodologies to strengthen guideline positioning, influence payer decisions, and accelerate coverage for an oncology drug's extended indication.
📈
Value Framework Strategy
Both
Public & Private Payers
✓
Coverage Accelerated
3
Frameworks Analyzed
Cat 2A
NCCN Recommendation
the challenge
Competing in a Framework-Driven Market
The increasing influence of oncology value frameworks was directly impacting payer decisions for an oncology drug seeking coverage for an extended indication. Without strategic positioning, the drug risked being deprioritized in formulary decisions.
Competitors had already established their positioning with more mature datasets, and the lack of standardization among frameworks each with different methodologies and criteria meant a one-size-fits-all approach wouldn't work.
"The company needed a sophisticated strategy to navigate each framework while building a coherent overall value story."
Our Approach
Multi-Framework Strategic Analysis
We conducted comprehensive analysis across the three major oncology value frameworks, developing tailored strategies for each.
01
NCCN Evidence Blocks
Simulated likely categorization and developed messaging to ensure optimal guideline inclusion and Category 2A recommendation.
02
ASCO Value Framework
Analyzed clinical benefit scores and identified opportunities to strengthen positioning based on efficacy, toxicity, and symptom palliation.
03
ICER Methodology
Modeled alternative cost-effectiveness scenarios to anticipate and mitigate potential negative assessments through real-world outcome evidence.
04
Unified Value Messaging
Developed coherent talking points that translated framework-specific evidence into practical payer conversations.
"
A strong NCCN strategy ultimately led to accelerating coverage and reimbursement for an extended indication with both private and public payers.
Engagement Outcome
the results
Multi-Framework Success
The comprehensive framework analysis delivered results across multiple dimensions, strengthening positioning with guidelines and payers alike.
🛡️
Mitigated
ICER risk through alternative economic analyses
📋
Cat 2A
NCCN guideline recommendation achieved
💰
Faster
Coverage decisions with public and private payers
key insights
Framework Strategy Best Practices
1
Each Framework Requires Tailored Approach
NCCN, ASCO, and ICER use different methodologies—effective strategy requires understanding and addressing each on its own terms.
2
Simulation Prevents Surprises
Projecting likely framework categorization before submission allows proactive messaging development and data gap identification.
3
RWE Can Counter ICER Concerns
Real-world outcome data provides alternative perspectives when trial-based cost-effectiveness analyses are unfavorable.
4
NCCN Category 2A Is the Coverage Threshold
For most payers, this recommendation level is the minimum required for coverage consideration.
Navigating Value Frameworks?
Let's discuss how to optimize your positioning across NCCN, ASCO, ICER and other value assessment bodies.